PMID- 35686555
OWN - NLM
STAT- MEDLINE
DCOM- 20220613
LR  - 20220716
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 26
IP  - 2
DP  - 2022 Aug
TI  - Optimal combination of cationic lipid and phospholipid in cationic liposomes for 
      gene knockdown in breast cancer cells and mouse lung using siRNA lipoplexes.
LID - 253 [pii]
LID - 10.3892/mmr.2022.12769 [doi]
AB  - Formulation of cationic liposomes is a key factor that determine the gene 
      knockdown efficiency by cationic liposomes/siRNA complexes (siRNA lipoplexes). 
      Here, to determine the optimal combination of cationic lipid and phospholipid in 
      cationic liposomes for in vitro and in vivo gene knockdown using siRNA 
      lipoplexes, three types of cationic lipid were used, namely 
      1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), dimethyldioctadecylammonium 
      bromide (DDAB) and 
      11-[(1,3-bis(dodecanoyloxy)-2-((dodecanoyloxy)methyl)propan-2-yl)amino]-N,N,N-trimethyl-11-oxoundecan-1-aminium 
      bromide (TC-1-12). Thereafter, 30 types of cationic liposome composed of each 
      cationic lipid with phosphatidylcholine or phosphatidylethanolamine containing 
      saturated or unsaturated dialkyl chains (C14, C16, or C18) were prepared. The 
      inclusion of phosphatidylethanolamine containing unsaturated and long dialkyl 
      chains with DOTAP- or DDAB-based cationic liposomes induced strong luciferase 
      gene knockdown in human breast cancer MCF-7-Luc cells stably expressing 
      luciferase gene. Furthermore, the inclusion of phosphatidylcholine or 
      phosphatidylethanolamine containing saturated and short dialkyl chains or 
      unsaturated and long dialkyl chains into TC-1-12-based cationic liposomes 
      resulted in high gene knockdown efficacy. When cationic liposomes composed of 
      DDAB/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), TC-1-12/DOPE and 
      TC-1-12/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine were used, 
      significant gene knockdown occurred in the lungs of mice following systemic 
      injection of siRNA lipoplexes. Overall, the present findings indicated that 
      optimal phospholipids in cationic liposome for in vitro and in vivo siRNA 
      transfection were affected by the types of cationic lipid used.
FAU - Hattori, Yoshiyuki
AU  - Hattori Y
AD  - Department of Molecular Pharmaceutics, Hoshi University, Tokyo 142-8501, Japan.
FAU - Tang, Min
AU  - Tang M
AD  - Department of Molecular Pharmaceutics, Hoshi University, Tokyo 142-8501, Japan.
FAU - Torii, Satomi
AU  - Torii S
AD  - Department of Molecular Pharmaceutics, Hoshi University, Tokyo 142-8501, Japan.
FAU - Tomita, Kana
AU  - Tomita K
AD  - Department of Molecular Pharmaceutics, Hoshi University, Tokyo 142-8501, Japan.
FAU - Sagawa, Ayane
AU  - Sagawa A
AD  - Department of Molecular Pharmaceutics, Hoshi University, Tokyo 142-8501, Japan.
FAU - Inoue, Nodoka
AU  - Inoue N
AD  - Department of Molecular Pharmaceutics, Hoshi University, Tokyo 142-8501, Japan.
FAU - Yamagishi, Reo
AU  - Yamagishi R
AD  - Department of Molecular Pharmaceutics, Hoshi University, Tokyo 142-8501, Japan.
FAU - Ozaki, Kei-Ichi
AU  - Ozaki KI
AD  - Department of Molecular Pathology, Faculty of Pharmaceutical Sciences, Doshisha 
      Women's College of Liberal Arts, Kodo, Kyotanabe, Kyoto 610-0395, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220610
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Cations)
RN  - 0 (Liposomes)
RN  - 0 (Phosphatidylcholines)
RN  - 0 (Phosphatidylethanolamines)
RN  - 0 (Phospholipids)
RN  - 0 (RNA, Small Interfering)
RN  - EC 1.13.12.- (Luciferases)
SB  - IM
MH  - Animals
MH  - Cations
MH  - Female
MH  - *Gene Knockdown Techniques
MH  - Humans
MH  - *Liposomes
MH  - Luciferases
MH  - Lung
MH  - MCF-7 Cells
MH  - Mice
MH  - Phosphatidylcholines
MH  - Phosphatidylethanolamines
MH  - Phospholipids
MH  - RNA, Small Interfering/genetics
MH  - Transfection
PMC - PMC9218728
OTO - NOTNLM
OT  - cationic liposome
OT  - gene knockdown
OT  - lung
OT  - phospholipid
OT  - siRNA delivery
COIS- The authors declare that they have no competing interests.
EDAT- 2022/06/11 06:00
MHDA- 2022/06/14 06:00
PMCR- 2022/06/10
CRDT- 2022/06/10 05:03
PHST- 2022/02/22 00:00 [received]
PHST- 2022/05/12 00:00 [accepted]
PHST- 2022/06/10 05:03 [entrez]
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/06/14 06:00 [medline]
PHST- 2022/06/10 00:00 [pmc-release]
AID - 253 [pii]
AID - MMR-26-02-12769 [pii]
AID - 10.3892/mmr.2022.12769 [doi]
PST - ppublish
SO  - Mol Med Rep. 2022 Aug;26(2):253. doi: 10.3892/mmr.2022.12769. Epub 2022 Jun 10.